BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

8756 related articles for article (PubMed ID: 1768370)

  • 1. Single-dose murine monoclonal antibody ricin A chain immunotoxin in the treatment of metastatic melanoma: a phase I trial.
    Gonzalez R; Salem P; Bunn PA; Zukiwski AA; Lamb R; Benjamin RS; Spitler L; Wedel N; Robinson WA
    Mol Biother; 1991 Dec; 3(4):192-6. PubMed ID: 1768370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin.
    Spitler LE; del Rio M; Khentigan A; Wedel NI; Brophy NA; Miller LL; Harkonen WS; Rosendorf LL; Lee HM; Mischak RP
    Cancer Res; 1987 Mar; 47(6):1717-23. PubMed ID: 3493066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma.
    Schnell R; Staak O; Borchmann P; Schwartz C; Matthey B; Hansen H; Schindler J; Ghetie V; Vitetta ES; Diehl V; Engert A
    Clin Cancer Res; 2002 Jun; 8(6):1779-86. PubMed ID: 12060617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of monoclonal antibody-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer.
    Byers VS; Rodvien R; Grant K; Durrant LG; Hudson KH; Baldwin RW; Scannon PJ
    Cancer Res; 1989 Nov; 49(21):6153-60. PubMed ID: 2790828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II study of murine monoclonal antibody-ricin A chain (XOMAZYME-Mel) immunoconjugate plus cyclosporine A in patients with metastatic melanoma.
    Selvaggi K; Saria EA; Schwartz R; Vlock DR; Ackerman S; Wedel N; Kirkwood JM; Jones H; Ernstoff MS
    J Immunother Emphasis Tumor Immunol; 1993 Apr; 13(3):201-7. PubMed ID: 8471594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity and immunogenicity of monoclonal antimelanoma antibody-ricin A chain immunotoxin in rats.
    Harkonen S; Stoudemire J; Mischak R; Spitler LE; Lopez H; Scannon P
    Cancer Res; 1987 Mar; 47(5):1377-82. PubMed ID: 3493064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimelanoma monoclonal antibody-ricin A chain immunoconjugate (XMMME-001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: results of a phase II trial.
    Oratz R; Speyer JL; Wernz JC; Hochster H; Meyers M; Mischak R; Spitler LE
    J Biol Response Mod; 1990 Aug; 9(4):345-54. PubMed ID: 2395000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: effect of an intensive schedule of administration.
    Conry RM; Khazaeli MB; Saleh MN; Ghetie V; Vitetta ES; Liu T; LoBuglio AF
    J Immunother Emphasis Tumor Immunol; 1995 Nov; 18(4):231-41. PubMed ID: 8680651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human antibody responses to components of the monoclonal antimelanoma antibody ricin A chain immunotoxin XomaZyme-MEL.
    Mischak RP; Foxall C; Rosendorf LL; Knebel K; Scannon PJ; Spitler LE
    Mol Biother; 1990 Jun; 2(2):104-9. PubMed ID: 2363853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of cyclophosphamide on the toxicity and immunogenicity of ricin A chain immunotoxin in rats.
    Stoudemire JB; Mischak R; Foxall C; Harkonen WS; Del Rio M; Spitler LE
    Mol Biother; 1990 Sep; 2(3):179-84. PubMed ID: 2222902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma.
    Grossbard ML; Multani PS; Freedman AS; O'Day S; Gribben JG; Rhuda C; Neuberg D; Nadler LM
    Clin Cancer Res; 1999 Sep; 5(9):2392-8. PubMed ID: 10499609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate.
    Weiner LM; O'Dwyer J; Kitson J; Comis RL; Frankel AE; Bauer RJ; Konrad MS; Groves ES
    Cancer Res; 1989 Jul; 49(14):4062-7. PubMed ID: 2786751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and toxicology of immunotoxins administered into the subarachnoid space in nonhuman primates and rodents.
    Muraszko K; Sung C; Walbridge S; Greenfield L; Dedrick RL; Oldfield EH; Youle RJ
    Cancer Res; 1993 Aug; 53(16):3752-7. PubMed ID: 8339287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma.
    Multani PS; O'Day S; Nadler LM; Grossbard ML
    Clin Cancer Res; 1998 Nov; 4(11):2599-604. PubMed ID: 9829722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I immunotoxin trial in patients with B-cell lymphoma.
    Vitetta ES; Stone M; Amlot P; Fay J; May R; Till M; Newman J; Clark P; Collins R; Cunningham D
    Cancer Res; 1991 Aug; 51(15):4052-8. PubMed ID: 1855219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials.
    Schindler J; Sausville E; Messmann R; Uhr JW; Vitetta ES
    Clin Cancer Res; 2001 Feb; 7(2):255-8. PubMed ID: 11234876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of monoclonal antibody-ricin A chain immunoconjugate Xomazyme-791 in patients with metastatic colon cancer.
    LoRusso PM; Lomen PL; Redman BG; Poplin E; Bander JJ; Valdivieso M
    Am J Clin Oncol; 1995 Aug; 18(4):307-12. PubMed ID: 7625372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.
    Sosman JA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Weiss GR; Isaacs RE; Margolin KA; Fisher RI; Ernest ML; Mier J; Oleksowicz L; Eckhardt JR; Levitt D; Doroshow JH
    Clin Cancer Res; 1997 Jan; 3(1):39-46. PubMed ID: 9815535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superantigen-targeted therapy: phase I escalating repeat dose trial of the fusion protein PNU-214565 in patients with advanced gastrointestinal malignancies.
    Alpaugh RK; Schultz J; McAleer C; Giantonio BJ; Persson R; Burnite M; Nielsen SE; Vitek L; Persson B; Weiner LM
    Clin Cancer Res; 1998 Aug; 4(8):1903-14. PubMed ID: 9717818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy of metastatic malignant melanoma using Xomazyme Mel, a murine monoclonal anti-melanoma ricin A chain immunotoxin.
    Spitler LE; Mischak R; Scannon P
    Int J Rad Appl Instrum B; 1989; 16(6):625-7. PubMed ID: 2606718
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 438.